HIV vac­cine re­mains Holy Grail as Sanofi/GSK reg­i­men dis­ap­points in large study

6 years ago
R&D

Bio­Mo­tiv, Bris­tol-My­ers al­liance bears fruit with new com­pa­ny: An­teros Phar­ma

6 years ago
Deals
R&D

Re­gen­eron joins the hunt for an­ti­bod­ies to fight a brew­ing pan­dem­ic as re­searchers whip up new tri­als for an­tivi­rals

6 years ago
R&D

Too slow to warn: Sanofi in­dict­ed over old an­ti-epilep­tic drug tied to birth de­fects

6 years ago
Pharma
FDA+

Q&A with Jorge Conde as An­dreessen Horowitz launch­es $750M bio fund III

6 years ago
Financing

In­smed’s PhII smokes and sput­ters, but re­searchers her­ald enough sur­pris­ing­ly pos­i­tive da­ta to roar on Wall Street

6 years ago
R&D

Court sides with FDA in Van­da clin­i­cal hold suit

6 years ago
FDA+

F-Prime backs a niche AI soft­ware start­up hunt­ing lofty goals in $22M Se­ries B

6 years ago
Financing
Startups

How much does it cost to boot­strap a gene ther­a­py start­up? Not too much if you're Jim Wil­son, per Pas­sage Bio's $125M ...

6 years ago
Financing
Cell/Gene Tx

Failed piv­otal study? You can still have break­through ther­a­py sta­tus — FDA sig­nals to Resver­logix

6 years ago
R&D

Rev­o­lu­tion Med­i­cines shoots for $150 mil­lion IPO; No­var­tis vet heads to Boston Phar­ma

6 years ago
News Briefing

GAO re­port rais­es ques­tions about reau­tho­riz­ing two PRV pro­grams

6 years ago
FDA+

Pan­dem­ic fears force Chi­nese biotech to post­pone Hong Kong IPO meet­ings — Bloomberg

6 years ago
Financing
China

Unit­ed Ther­a­peu­tic­s' drug fails PhII/III can­cer tri­al, mark­ing their sec­ond straight stum­ble in post-Re­mod­ulin PAH

6 years ago
R&D

Roche vet San­dra Horn­ing jumps on bio­phar­ma board no. 3 — what’s that worth?

6 years ago
R&D

Catal­ent chief John Chimin­s­ki trig­gers a $315M-plus wa­ger on the boom­ing cell ther­a­py mar­ket now in the mak­ing

6 years ago
Deals
Outsourcing

Bris­tol-My­ers with­draws Op­di­vo/Yer­voy lung can­cer EU ap­pli­ca­tion — but oth­ers are in­com­ing

6 years ago
R&D

The pow­er of prece­dent: How a one-off de­ci­sion by Janet Wood­cock es­tab­lished an un­in­tend­ed fast path­way at the FDA ...

6 years ago
Bioregnum
Opinion

Gilead surges wild­ly as world scram­bles to counter a like­ly coro­n­avirus pan­dem­ic while GSK pitch­es in on vac­cine R&D ...

6 years ago
Pharma
Coronavirus

Aim­mune wins ap­proval for peanut im­munother­a­py, charges 10k+

6 years ago
Pharma
FDA+

Cure­Vac jumps in­to coro­n­avirus vac­cine race; EMA backs raft of drugs, in­clud­ing No­vo Nordisk, Es­pe­ri­on com­pounds

6 years ago
News Briefing
Coronavirus

Biotech was big in 2019, but here's one record no one want­ed to see bro­ken: Most bank­rupt­cies

6 years ago
Pharma

Out­go­ing CEO Jeff Lei­den takes vic­to­ry lap as Ver­tex's Trikaf­ta stuns Wall Street

6 years ago
R&D
Pharma

Striv­ing for high­er res imag­ing of cells, Har­vard team de­buts start­up with back­ing from ARCH, North­pond

6 years ago
Financing
Startups
First page Previous page 865866867868869870871 Next page Last page
A service from the Financial Times